Kodiak Sciences Inc.
Close on Oct 19, 2026
- Market cap
- $5.72B
- P/E (TTM)
- –
- Dividend yield
- –
About Kodiak Sciences
Biological Products, (No Diagnostic Substances), SIC 2836
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on preventing and treating leading causes of blindness. Utilizing its proprietary Antibody Biopolymer Conjugate platform, the company designs therapeutics for patients with retinal vascular diseases and ocular inflammation. Its pipeline includes tarcocimab tedromer, an investigational anti-VEGF therapy undergoing Phase 3 clinical evaluation for conditions such as diabetic retinopathy and wet age-related macular degeneration. Kodiak is also advancing KSI-501, a bispecific therapy targeting interleukin-6 and VEGF, and KSI-101 for macular edema secondary to inflammation. Additionally, the company develops expanded conjugate technologies and digital health platforms.
The company operates globally, retaining worldwide rights to develop, manufacture, and commercialize its investigational medicines. Its infrastructure includes Ursus, a custom-designed, commercial-scale drug substance manufacturing facility commissioned in partnership with Lonza. Kodiak conducts multicenter clinical trials across various international study sites. The provided text does not state the company's specific headquarters location.
Summary of the business section of Kodiak Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Kodiak Sciences Inc.
- Founded
- 2009
- Headquarters
- Palo Alto, CA
- Address
- 1250 Page Mill Rd 94304
- Phone
- (650) 281-0850
- Website
- kodiak.com
- Employees
- 124, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- KOD
- Exchange
- Nasdaq
- IPO date
- Oct 5, 2018
- Shares outstanding
- 63M, Aug 6, 2026
- Public float
- $121.60M, Jun 28, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1468748
- CUSIP
- 50015M109
- ISIN
- US50015M1099
- LEI
- 254900IXI5NI8C9OQE24
- EIN
- 27-0476525
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Victor Perlroth | Chairman and CEO, Director | 3,732,242 |
| John A. Borgeson | Chief Financial Officer | 216,034 |
| Julian Baker | Director | 19,221,341 |
| Felix Baker | Director | 15,455,507 |
| Brothers Life Sciences LP Baker | Director | 18,358,772 |
| Bros. Advisors (GP) LLC Baker | Director | 18,373,116 |
| 667, L.P. | Director | 1,669,727 |
| Bros. Advisors Lp Baker | Director | 14,364,512 |
| Richard S. Levy | Director | 250 |
| Robert Profusek | Director | 10,000 |
| Taiyin Yang | Director | 0 |
| Bassil I. Dahiyat | Director | – |
| Charles A. Bancroft | Director | 25,948 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Victor Perlroth | $2.50M | $24.35M | $1.62M | $391 | – |
| FY2024 Victor Perlroth | $1.99M | $11.28M | $1.36M | $12 | – |
| FY2023 Victor Perlroth | $2.73M | -$830.47K | $1.54M | $4 | – |
| FY2022 Victor Perlroth | $3.00M | -$118.83M | $1.57M | $8 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 124 employees worldwide, of whom 10 were based outside of the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 10, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 5, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 1, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 28, 2009 | Name change | Name changed from Oligasis, LLC to Kodiak Sciences Inc. |